Top 20 Pharmas

7/31/2019 Top 20 Pharmas

1/8

Top 20 Pharmasbased on 2010 revenues, in millions

1 Pfizer $58,5232 Novartis $44,4203 Merck &Co. $39,8114 Sanofi $37,4035 GlaxoSmithKline $36,156

6 AstraZeneca $32,5157 Johnson &Johnson $22,3968 Eli Lilly &Co. $21,6859 Abbott Laboratories $19,89410 Bristol-Myers Squibb $19,48411 Teva $16,12112 Takeda Pharma $14,82913 Bayer Schering $14,48514 Boehringer-Ingelheim $12,88315 Astellas $11,16116 Daiichi-Sankyo $10,79417 EISAI $8,54218 Otsuka Pharmaceutical $8,44019 Gilead Sciences $7,39020 Mylan $5,404

Regulated to unregulated refers to the spectrum of control a govt institutes in the pharmaceutical industry, from requiring papers of

R&D depts, reviewing results ofclinical drug trials, and controlling the environment in which a drug is manufactured through toughlicensing laws. Some countries make you jump through hoops, others could care less, or they have laws in writing which are not

diligently enforced.

The changing dynamics of the global pharmaceutical industry especially that of the regulated markets like USA and Europe have

presented a number of opportunities forIndian Pharmaceutical Industry to capitalize on.

Japan, the world's third largest and one of the most regulated pharmaceutical marketsglobally, is emerging as the new attractive

destination for Indian drug majors.

The Latin American (Latam) pharmaceutical market is a semi-regulated market. Brazil is the largest pharmaceutical market in South

America and ranks eleventh globally. It is an attractive semi-regulated market, offering immense opportunities for speciality

pharmaceutical companies, Glenmark said.

The Government of Lebanon continuously tries to control and limit medication costs. The market for medications, whichaccounts for 35-40 percent of health care expenditures, is largely unregulated

Market Failure and the Pharmaceutical Industry: A Proposal for ReformBy Sean Gabb www.seangabb.co.uk

September 30, 2005

The award last month of 141m ($250m) against Merck for the alleged deficiencies of its painkilling drug Vioxx has brought thewhole pharmaceutical industry into public discussion. We can, of course, deplore the vagaries of the American legal system. It isunlikely that the plaintiff in this particular case will ever see much of her compensation. The award will be contested in appeal afterappeal. These will drag on for years to the ultimate enrichment only of the lawyers concerned. The case does, nevertheless, raisegeneral issues of how the pharmaceutical industry conducts itself.There can be no doubt that the pharmaceutical industry as a whole has achieved and is achieving what would once have beenregarded as miracles. It has created new products that cure or alleviate sickness and that have extended both the length andquality of life. This much has been achieved so far. There is every reason to believe that the future will bring still greater progress.Even so, the pharmaceutical companies have never been popular in the way that companies like Compaq and Apple Mackintoshhave managed to become. They are distrusted where not actively disliked. The present case against Merck is just one instance of agrowing prejudice.Since the 9th September 2004, the Health Select Committee of the House of Commons has been examining the influence in Britainof the pharmaceutical industry. The Committee is looking at how the industry affects government, regulators, healthcareprofessionals and consumers, and at the effects of this influence on public health. It has examined witnesses and consideredwritten submissions by interested persons and organisations. The hearings began as a result of the obvious disquiet over thebehaviour of the pharmaceutical companies.To be fair, there is some reason for disquiet. The pharmaceutical companies are limited companies, and their first duty is tomaximise the return on their investments for dividing among their shareholders. As said, they have done and are doing often
http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/01-pfizer---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/01-pfizer---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/02-novartis---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/02-novartis---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/04-sanofi---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/04-sanofi---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/05-glaxosmithkline---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/05-glaxosmithkline---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/06-astrazeneca---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/06-astrazeneca---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/09-abbott-laboratories---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/09-abbott-laboratories---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/10-bristol-myers-squibb---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/10-bristol-myers-squibb---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/11-teva-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/11-teva-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/12-takeda-pharmaceutical-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/12-takeda-pharmaceutical-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/13-bayer-healthcare---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/13-bayer-healthcare---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/14-boehringer-ingelheim---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/14-boehringer-ingelheim---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/15-astellas-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/15-astellas-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/16-daiichi-sankyo-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/16-daiichi-sankyo-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/17-eisai---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/17-eisai---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/18-otsuka-pharmaceutical-group---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/18-otsuka-pharmaceutical-group---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/19-gilead-sciences-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/19-gilead-sciences-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/20-mylan-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/20-mylan-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/20-mylan-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/20-mylan-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/20-mylan-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/19-gilead-sciences-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/19-gilead-sciences-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/19-gilead-sciences-inc---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/18-otsuka-pharmaceutical-group---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/18-otsuka-pharmaceutical-group---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/18-otsuka-pharmaceutical-group---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/17-eisai---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/17-eisai---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/17-eisai---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/16-daiichi-sankyo-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/16-daiichi-sankyo-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/16-daiichi-sankyo-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/15-astellas-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/15-astellas-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/15-astellas-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/14-boehringer-ingelheim---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/14-boehringer-ingelheim---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/14-boehringer-ingelheim---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/13-bayer-healthcare---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/13-bayer-healthcare---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/13-bayer-healthcare---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/12-takeda-pharmaceutical-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/12-takeda-pharmaceutical-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/12-takeda-pharmaceutical-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/11-teva-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/11-teva-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/11-teva-pharma---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/10-bristol-myers-squibb---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/10-bristol-myers-squibb---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/10-bristol-myers-squibb---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/09-abbott-laboratories---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/09-abbott-laboratories---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/09-abbott-laboratories---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/08-eli-lilly-co---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/07-johnson-johnson---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/06-astrazeneca---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/06-astrazeneca---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/06-astrazeneca---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/05-glaxosmithkline---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/05-glaxosmithkline---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/05-glaxosmithkline---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/04-sanofi---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/04-sanofi---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/04-sanofi---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/03-merck---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/02-novartis---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/02-novartis---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/02-novartis---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/01-pfizer---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/01-pfizer---2011-top-20-pharma-report/http://www.contractpharma.com/contents/view_top-companies-report/2011-07-14/01-pfizer---2011-top-20-pharma-report/


2/8

marvellous things. But they have also been caught many times engaged in questionable or even immoral conduct. Let us considersome of this conduct, most though not all of it revealed to the Committee.

The Case against the Pharmaceutical Companies

Underhand Promotion

In 1998, GlaxoSmithKline published an internal memorandum, Towards the Second Billion a reference to sales of $1 billionalready in which it discussed marketing strategies by which sales of Seroxat could be increased. This is a powerful anti-depressant, and it was suggested that sales might be increased by persuading people to take it who were not seriously

depressed.[1]

Pharmaceutical companies run disease awareness campaigns, in which, according to Dr Iona Heath, speaking before theCommons Health Select Committee, they deliberately frighten patients about conditions that are not serious enough to requirespecial medication, and thereby increase pressure on general practitioners to prescribe those medications. She calls this apolicy of deliberate disease creep.[2]

Pharmaceutical companies have been accused of setting up front groups to urge sale of their products. In April 2000, forexample, Schering Healthcare and Biogen Ltd were investigated by the Commons Select Health Committee for fundingapparently independent campaigning groups, which set up websites and bought advertising space in newspapers torecommend their products to the public.[3]

Pharmaceutical companies seek to influence general practitioners to prescribe their new products by inviting them toconferences in expensive locations, where they are given lavish hospitality and are loaded with presents.

According to Professor David Healy of the University of Wales, the pharmaceutical companies regularly arrange forendorsements of their products to be published in the medial press. He told the Commons Health Select Committee in October2004 that as many as half the articles published in journals such as The British Medical Journaland The Lancetwere ghostwritten for the pharmaceutical companies, and that respected clinicians were then paid to have their names put at the top of

the articles, even though they had not seen the raw data on which they were based. He gave the example of an article he hadrefused to father that later appeared bearing the name of Siegfried Kasper, from the Department of General Psychiatry at theUniversity of Vienna.[4]

Doctors are paid large fees for giving apparently spontaneous endorsements of pharmaceutical products to other doctors.Apparently, some senior medical consultants receive consultancy fees of more than 20,000 for a few hours work. Experts canalso earn more than 4,000 an hour for extolling the virtues of new drugs to other doctors.[5]

According to the Royal College of General Practitioners, giving evidence in August 2004 to the Commons Health SelectCommittee, normal variations in peoples health are now arbitrarily being classified as diseases and that companies are moreinterested in selling preventative drugs to the healthy than in healing the sick. It calls this practice disease mongering.[6]

Marketing Ineffective or Dangerous Products

Large amounts of money are spent on marketing products which do not work. The medications presently used to treatAlzheimers disease have been said by the companies producing them to have impressive results. But it now emerges that theyhave little impact on halting the progression of the disease or allowing people a better quality of life.[7]

Worse than this, two drugs, often prescribed for dementia, may not only be ineffective but one may even accelerate mentaldecline. Quetiapine (sold as Seroquel) and rivastigmine (Exelon) are prescribed to nearly half the patients with dementia in

residential homes in Britain, often for long periods. Patients are given the drugs to control behavioural changes such asagitation, which are disturbing to them and make them more difficult to look after. But a trial in Newcastle has suggested thatthe drugs are ineffective and, in the case of quetiapine, accelerate the progress of the disease. The trial, funded by the

Alzheimers Research Trust, involved 93 people with Alzheimers living in care homes in Newcastle. It was led by Clive Ballard,of the Institute of Psychiatry at Kings College London. The patients were treated with quetiapine, rivastigmine or a placebopill. Neither of the groups given the active drugs showed any benefit in their agitation symptoms over six months. Those givenquetiapine showed a much more rapid decline in mental capacities. A report published in The British Medical Journalsays thatit should not be used to treat such patients.[8]

In February 2005, patients taking any Cox-2 inhibitors which include Celebrex, Bextra and Arcoxia, these being used to treatpain and inflammation in osteoarthritis and rheumatoid arthritis, and in the management of acute pain were officially advisedto stop their treatment immediately if they suffered from heart disease or stroke The European Medicines Agency said thatpatients on Cox-2 inhibitors, anti-inflammatory drugs used by more than a million Britons, should observe urgent safetyrestrictions after a comprehensive review. This action came after growing concerns about evidence suggesting a raised risk ofheart attacks or strokes linked to the class of drugs. Doctors were instructed to exercise caution in prescribing to any patientswho might be at increased risk of heart disease such as smokers, diabetics and sufferers of hypertension and high

cholesterol.[9] Vioxx, another bestselling painkiller, was withdrawn by the pharmaceutical company Merck in September 2004 after a study of

cancer patients showed a similar increased risk. Vioxx had been prescribed to 400,000 Britons at the time, many of whomwere then given Celebrex and Arcoxia instead.[10] The present award of 141m may be followed by claims of ten or twentytimes this amount by British litigants alone.

Unethical Behaviour

Pharmaceutical companies pay general practitioners to test their new products on patients. Some of these tests are secret. Insome cases, patients are given medications they do not need. At the same time, other patients are denied medications theyneed, so they can be used to measure the effectiveness of the tests. In 2002, for example, Dr Robert Adams testedParoxetine, a new anti-depressant produced by GlaxoSmithKline, on a patient without her knowledge and consent. Shesuffered severe side effects. An investigation by the General Medical Council found that Dr Adams had received more than


3/8

100,000 during the previous five years from various companies, and that many of the tests had also been run without theconsent of his patients. According to an investigation by The Observernewspaper, there are around 45,000 such trials everyyear, bringing general practitioners around 1,000 per patient even if only about one per cent of these trials are run withoutconsent, and if the companies sponsoring them are not implicated in these trials.[11]

Some pharmaceutical companies are seeking to end the practice of parallel imports, whereby products are imported into thiscountry from other countries where the products are sold at lower prices. GlaxoSmithKline, for example, is accused of settingmaximum order sizes on wholesalers in cheaper countries, the effect of which is to force up demand for the products in thiscountry from the manufacturers.[12]

Suppression of Unwelcome Information

Pharmaceutical companies only publish trial reports favourable to their products. GlaxoSmithKline, for example, is alleged tohave withheld information that Seroxat increased the risk of suicide in children. Since the information was published, Seroxathas been banned from prescription to persons under the age of 18.[13]

A pharmaceutical company was accused before the Commons Health Select Committee in November 2004 of having offeredPeter Wilmshurst, consultant cardiologist at the Royal Shrewsbury Hospital two years salary to suppress results of a trial thatshowed its products were both deadly and ineffective. He refused the bribe and the drug was subsequently banned after hisresults were published.[14] He explained to the Committee: I know the pharmaceutical industry influences the research thatis published. I suspect this is as common now as ever. I think it is very common. People are influenced by opinion leaders whoare paid consultants to the company.

The War against Vitamins

For many years now, the pharmaceutical companies have been accused of working to limit access to vitamins and other dietarysupplements. The main vehicle for this limitation is the Codex Alimentarius. This is an organisation set up in 1962 and affiliated tothe United Nations. Its purpose is to harmonise regulations across the world on a range of issues related to food. For the past

decade or so, it has been working in conjunction with the main pharmaceutical companies to destroy the growing market in dietarysupplements.On the 4th July this year, it recommended laws in every country to require labelling that contains information on maximumconsumption levels of vitamins and mineral food supplements, assisting countries to increase consumer information, which will helpconsumers use them in a safe and effective way.... The guidelines say that people should be encouraged to select a balanced dietto get the sufficient amount of vitamins and minerals. Only in cases where food does not provide sufficient vitamins and mineralsshould supplements be used.So long as the Codexwas purely a creature of the United Nations, its recommendations were of little importance. They could beadopted or ignored as member states pleased, and most governments generally ignored them. Since the early 1990s, however,the Codexhas been recognised by the World Trade Organisation. All member states are now obliged by treaty to incorporate theprovisions of the Codexinto their domestic law. Failure to do this may lead to international sanctions and even expulsion from theWorld Trade Organisation.The European Union has already imposed its own regulations. On the 1st August this year, the Food Supplements Directive, basedon 1998 German regulations that emphasize maximum upper limits, came into force.[15] If ever carried fully into effect, this willtake as many as 5,000 products off the European market. The Directive does not explicitly require bans on any products. It insteadlays down rules on testing that will for reasons of cost prevent most supplements from remaining on the market. It also requires

limitations on dosages that can be sold without a medical prescription.The meaning of this Directive is explained in a British Government news release:The Food Supplements Directive 2002/46/EC came into force in July 2002 and was implemented in England by the FoodSupplements (England) Regulations 2003. Separate, equivalent legislation has been made in Scotland, Wales and Northern Ireland.The directive and these regulations apply from 1 August 2005.One of the provisions of this directive is for lists of nutrients and their sources that can be included in food supplements. The firstlist covers the vitamins and minerals that may be used in food supplements (such as vitamin C, calcium, iron). It excludes sixminerals (tin, silicon, nickel, boron, cobalt, and vanadium) that are currently used in food supplements on sale in the UK.The second list covers the chemical forms (sources) of those vitamins and minerals that may be used. These lists can be added tofollowing a favourable opinion on individual nutrients or nutrient sources from the European Food Safety Authority (EFSA) afterconsideration of a dossier containing safety data.[16]Now, there are two positions on dietary supplements. One is to regard them as useful simply to prevent illnesses caused bydeficiencies, like scurvy, beriberi and pellagra. The semi-official recommended daily allowances, which can be seen on every label,are based crudely on the estimated dosage needed to prevent deficiency.On this reasoning, dietary supplements have their use at times and in places where people cannot eat a full and balanced diet. Butthey are at best useless in wealthy countries like Britain and America, where just about everyone can have all the food he wants toeat. In some cases, they can be dangerous.The other position is to regard dietary supplements as active contributors to health and longevity. The recommended dailyallowances are regarded as minimum doses. The full potential of these supplements can only be realised at far higher doses. LinusPauling, for example who developed the polio vaccine believed that taking very large doses of vitamin C could prevent and insome cases even cure cancer. There is a huge literature or varying quality which suggests that the high, regular intake of certaindietary supplements can prevent or alleviate or cure many other illnesses, and can often achieve better results than the patentedmedications of the pharmaceutical industry.These are both arguable positions. Given the right environment of diversity, the dispute might long since have been settled byexperience. The problem is that, while no compelling evidence has been presented against them, it is widely believed that thepharmaceutical companies have decided that their interests are best served by having the first position imposed by law.


4/8

Controls on dietary supplements mean a bigger market for patented medicines than would otherwise exist. They also provideregulatory hurdles that restrict the market to those big pharmaceutical companies able and willing to pay for the necessarycertification.

In Partial Defence of the Pharmaceutical Companies

These are serious charges. Not all, however, are justly laid. Much criticism of the pharmaceutical industry seems to proceed from ageneral hostility to private business. And it seems to be taken for granted that profit is at least an indecent companion to the searchfor cures and palliatives for human illness. But what other model is there for the development of pharmaceutical products that

work? The Soviet and Chinese state pharmaceutical industries never amounted to much in terms of research and development ofproducts that were useful to ordinary people or even useful for their stated purpose. The private companies in the free world atleast do create new and useful products. And all this research and development costs money.Taking into account research and development and regulatory compliance, it costs about $800 million to bring a newpharmaceutical product to market.[17] Many of these costs are incurred whether or not the product is actually put onto the market.For every one new product put on the market, 5,000 chemical formulations do not make it: either they do not work as expected orthey are outperformed or simply beaten to market by a rival product. Once on the market, they have only a few years ofprofitability before the patent protection expires, or before an improved product is released by another company. A recent studyof 100 pharmaceutical products showed that the profits earned on most of them did not cover investment costs.[18]Therefore, it is entirely reasonable that the pharmaceutical companies should try to make a profit on those products that do cometo market.Parallel Imports

Turning to the issue of parallel imports, this is far most complex than the usual story of greedy pharmaceutical companies andheroic small firms undercutting them. The pharmaceutical companies adopt a strategy of contributive skim pricing. In the richercountries of the developed world, the price of a new product is set far above immediate costs of production, and even above its

own development cost. Some part of the resulting surplus may represent profit in the economic sense. In many cases, though, itwill be taken as a contribution to the general development costs of the company. In other words, those products that do succeedare priced to cover the costs of developing all products, whether or not successful.This allows pharmaceutical companies to charge lower prices in other countries, where people are too poor to pay the full cost priceof pharmaceutical products, but not too poor to buy at any price. In these countries, the pharmaceutical companies set prices tocover marginal cost of production plus whatever contribution to overheads can be charged. Companies distinguish betweenoverheads and marginal costs. Price must always cover the latter, but may include a variable contribution to the former. Prices inpoor countries are set to make a small contribution to research and development overheads, and a larger contribution is taken inrich countries. It makes economic sense, though the result is prices are largely determined by ability to pay, and patients in poorcountries receive a large indirect subsidy from patients in rich countries.The parallel trade threatens to destroy this subsidy to the poor. If people can buy pharmaceutical products at lower cost abroad,and re-import them, there is a short term fall in price. But the longer term consequences will be a shortage of investment funds forresearch and development of new products. Therefore, if steps are taken to limit the re-importation of products, these may be opento criticism in their specifics, but are not in themselves immoral business conduct.

How Can the Pharmaceutical Market be Improved?

But while there are defences to some of the charges, there is enough truth in the attack for the pharmaceutical industry to havefallen at least partially into disrepute in recent years. The pharmaceutical industry is seen as greedy, secretive and indifferent to thewishes or even needs of patients. It is also often seen as unable to create products that work effectively and safely. And the evidenttruth of these charges is being used as an argument for tighter regulation of how the pharmaceutical companies operate.The Consumers Association, for example, believes that the answer to the problems raised above is more and better regulation. Inits own submission of August 2004 to the Commons Health Select Committee, it argued The Medicines and Healthcare productsRegulatory Agency (MHRA) needs to ensure that all its work is undertaken in the interests of public health protection.[19] Itfurther argues:Responsibility for monitoring all forms of pharmaceutical industry advertising and other promotion should be transferred to a new,independent advertising and information regulator. This regulator should adopt and proactively implement robust and transparentprocedures to prevent misleading promotional campaigns - including all forms of covert promotion - as far as possible at the outset,and to take swift and effective action when these do occur. These procedures should be drawn up in consultation with all relevantparties, in particular, those representing the interests of patients, consumers and public health. Most importantly, they shouldmaintain a clear focus on protecting public health and delivering public benefit.[20]What reason, however, is there to suppose that regulation really is the solution to any of these problems? Undoubtedly, we live inan age where regulation is seen as the solution to every problem. As in the rest of the English-speaking world, Britain is subject to aheavy and growing weight of regulation. This is not the place to discuss whether any specific regulation is justified. It is enough tosay that there is a general assumption among those who matter that everything that is done by the people must be known to theauthorities and controlled by them.During the ten years to the 21st February 2005, the phrase completely unregulated occurs 153 times in the British newspaperpress. In all cases, unless used satirically, the phrase is part of a condemnation of some activity. We are told that the advertising offood to children,[21] residential lettings agents,[22] funeral directors,[23] rock climbing,[24] alleged communication with thedead,[25] salons and tanning shops,[26] contracts for extended warranties on home appliances,[27] and anything to do with theInternet - that these are all almost completely unregulated or just completely unregulated, and that the authorities had betterdo something about the fact.

Regulation: Solution or Problem?


5/8

Yet is regulation the solution in this case? The assumption behind much of what was presented to or discussed in the SelectCommittee hearings appears to have been that whatever wrong or merely questionable was done by the pharmaceutical companiescould have been avoided by a better scheme of regulation, and that, the problems uncovered, the best use of intellectual effortmust now be in devising a better scheme for the future. But what went wrong with the regulations already in place?The answer is that the present regulatory body for the pharmaceutical industry the Medicines and Healthcare Products Regulatory

Agency (MHRA) seems to have been too close to the industry for effective regulation to have taken place. In October 2004, TheGuardiannewspaper obtained documents that showed the nature of the relationship. Since 1989, when the then prime minister,Margaret Thatcher, took drug regulation out of the hands of the Department of Health, the MHRA has been wholly funded by the

pharmaceutical companies. Since then:

The regulator and the industry have been engaged in a joint lobbying campaign in Europe; The industry privately drew up its own detailed blueprint of how the MHRA should be run; The industry has been pushing for higher level representation at the MHRA against ministers wishes.[28]John Abraham, professor of sociology at Sussex University, who is mainly known for his books on drug regulation, says that theMHRA has come to believe the interests of public health are coherent with the promotion of the industry. He says:The criticism of the old Department of Health medicines department in the 70s was that it didnt have any teeth. Not only does itnow not have any teeth, but it is not motivated to bite.[29]He further claims that there is too much of the revolving door syndrome at the MHRA. Not only does it take fees from thepharmaceutical industry, but many agency officials used to work for pharmaceutical companies, such as the former head ofworldwide drug safety at GlaxoSmithKline, who is now the MHRAs head of licensing.It was with these facts in mind that the Consumers Association has called for a new regulatory body. However, what appears tohave happened with pharmaceutical regulation is not some aberration that can be improved with a new legal framework. It is nomore than the illustration of a general tendency.

The Case for Regulatory Bodies: Asymmetric Information as Market Failure

The justification for a regulatory body where pharmaceutical products are concerned is what economists call market failure. Themainstream defence of the free market rests on the claim that it allocates resources more efficiently than any other system. Tospeak formally, it tends to bring about both productive and allocative efficiency. This first means that goods and services areproduced at the lowest currently known cost. The second means that production satisfies the known wants of consumers in thefullest way currently possible.We can best see this argument in the analysis of firms under perfect competition. Let it be granted: that there are many buyers andsellers in a market; that all the goods produced in this market are of the same quality; that there are no barriers to entry or exit forany player in the market; that there is perfect knowledge among all players in the market regarding prices and production methods.Given these assumptions, an equilibrium between demand and supply will come about that maximises social welfare. Anyintervention by the authorities in such a state of affairs will produce a loss of welfare.Now, such an equilibrium never comes about in the real world. It certainly never comes about in the pharmaceutical productmarket. There are not large numbers of buyers and sellers, nor are goods of the same quality instead, there is a group of verylarge companies with virtual monopolies in certain products, facing a virtually monopsonistic buyer in each national market: inBritain, this is the National Health Service. There are obvious barriers to entry and exit. Above all, there is not perfect knowledge.There is instead what is called the problem of asymmetric information. The pharmaceutical companies know all that can be humanly

known about their products: the consuming public knows almost nothing, and is not thought able to learn what needs to be known.This being so, the overwhelming consensus of opinion is that some regulatory body is needed to stand between the pharmaceuticalcompanies and the consuming public. The functions of this body are to ask the appropriate questions, and only to allow products tobe sold if the answers are satisfactory. Given sufficient zeal by or trust in the regulatory body, there is no need for the public to askits own questions. Indeed, there is a case for the public not to be allowed to find out information for itself. The public may be tooill-informed about the nature of what is being discussed to understand the nature and quality of the information providedespecially as much information will come from sources that are themselves ill-informed. Therefore, in this country, the Medicinesand Healthcare Products Regulatory Agency. Therefore also bans on the advertising of pharmaceutical products, and a very tightcontrol over what information can be released to the public.The problems with this restrictive approach is that it does not work. As we have seen, the pharmaceutical companies will seek waysaround any controls. They will set up front organisations to campaign for certain products to be made available. They will also placewhat appear to be academic papers in the medical press that are in effect disguised advertisements, and will heavily promoteproducts directly to general practitioners. They may thereby ensure pressure on regulatory bodies to take a more liberal approachto licensing of products.

The Economics of Regulatory Capture

The main problem with this approach, however, is not incidental by systemic. It is what pubic choice economists call regulatorycapture.The phrase comes from Gabriel Kolko, a Marxist historian, who reworked his doctoral thesis into the The Triumph of Conservatism:

A Reinterpretation of American History, 1900-1916, published in 1963[30] and followed it up with a more detailed study of a singleindustry in Railroads and Regulationin 1965.[31] He applied the phrase to a specific phenomenon: when regulators serve theinterests of those they are allegedly regulating in the general public interest. It was known before Kolkos work, but regarded as anaberration. Kolko examined the growth of American federal regulation in the early 20th century, and argued that regulatory capturewas not just common, but in fact the norm. He found no important exception to its emerging, and usually emerging very early, inthe history of a regulatory agency. As the phrase "triumph of conservativism" suggests, Kolko argued that whatever liberalreformers might have intended, and whatever the public may have believed, business interests took control of the actual regulatoryprocess early on and made it work for them.


6/8

The basic mechanics of regulatory capture are straightforward. People give more attention to a particular law or agency if they feelthat they have something at stake. They will make sure to know about laws and policies that affect their own interests. If thosepeople are running a wealthy business, they will have a lot at stake, and will correspondingly make sure to be fully informed.Now, regulators may at first feel hostile to their subjects. Over time, however, regulators and the regulated get to know each otherand to work together, with or without any real sense of cooperation. The regulated, who provide information and make a show ofcooperation, earn the appreciation of regulators, who find that endless crusade takes its toll in energy, enthusiasm, and efficiency.Regulators find that if they cooperate with their subjects in some areas, they will get cooperation back on others.In addition, those of the regulated who gain the sympathy of regulators as "team players", "responsible, cooperative enterprises",

and the like get favours. The problem is that incremental small shifts can add up to big consequences. Over years and decades, thenet effect of such shifts in the course of regulation is to draw the regulatory agency in directions that the public is likely neither tounderstand nor to feel represents the original intent of the legislation that created the agency.There is no need for regulators and regulated to like each other. Often they do not. They still work together. Regulators hardly everwant to destroy what they regulate. Most often, they see their job as simply a matter of imposing the public interest on otherwiseirresponsible organisations. And the regulated usually regard the regulators as facts of life to deal with, and better cooperated withthan resisted outright.Regulated firms end up supplying not just data to regulators, but personnel. After all, who understands the field better than folkswho are retiring or resigning from the field's major participants? Few people want regulations made in outright ignorance. Theresult is a regulatory agency staffed by former or perhaps future colleagues of those in the regulated firms.Every so often, incidental details of this process will come to light. See, for example, The Guardianreport cited above. Sometimes,the details will verge on the scandalous see, for example, the revelations of the late 1990s about the body set up to regulate theBritish National Lottery. But the overwhelming evidence is that it is impossible to ensure that the regulators and regulated in anyscheme of regulation will not eventually come to regard each other in at least many important respects as allies, and to ensure thatregulation works in what objective third parties might regard as the public interest.

Safety in Diversity?Regulation, then, may not be the solution. Indeed, there may be no overall solution. Anyone who expects new pharmaceuticalproducts to be completely effective and completely safe and the pharmaceutical companies to love their customers more than theirbalance sheets, is asking for a perfection that cannot be on offer. We are talking about human beings. These have their owninterests to consult, and they never know the full consequences of their actions. New pharmaceutical products are usually based onradical new departures in scientific understanding; and it can never be known in advance what will the full effects will be. Testingon animals and on a small number of human volunteers can never give the same knowledge of effects that comes from having aproduct on the market for several years. Whatever model of supervision we adopt for the pharmaceutical industry, there willinevitably be failures medications that do not work, medications with unacceptable side effects, medications that are a deadlymenace to those who take them. It is unrealistic to expect otherwise.Nevertheless, we can hope to improve on the existing situation. The central questions are of information and trust. How can it begenerally known which pharmaceutical products work for patients? And how can we trust claims about what does work? Part of theanswer at least lies in diversity of information.

As said, we live in a world of centralised information about pharmaceutical products. Ordinary people are not expected or fullyallowed to learn for themselves about the value of any particular medication. Therefore, information about any specific product is oftwo kinds. First, there are the impenetrable and often secretive conversations that take place between the pharmaceuticalcompanies and the regulators of the medical profession or both. Second, there are the completely unregulated and frequentlyunlikely claims that circulate on the Internet some websites, for example, recommend Prozac as an appetite suppressant.[32]Between these extremes, there is at best limited room made for informed debate about pharmaceutical products.

Controlled Release of Information

Much has happened since the high age of confidence in government. But what Douglas Jay a Minister in the Labour Governmentof the day still largely holds:[I]n the case of nutrition and health, just as in the case of education, the gentleman in Whitehall really does know better what isgood for the people than the people know themselves.[33]We have an increasingly complex and dynamic pharmaceutical market in which it has been reasonable to see untrained members ofthe public as incompetent to make informed choices about products, and we have a medical profession and set of regulatoryagencies expected and empowered by law to make their choices for the public.That is why there are presently advertising controls in many European countries. These are now codified in the commercial lawcommon throughout the European Union. Directive 2001/83/EC on the Community code relates to medicinal products for humanuse. This Directive prohibits the advertising of prescription only medicines to the general public. Indeed, it goes further insuggesting that rules are needed for all pharmaceutical products, whether or not prescribed:

Advertising to the general public, even of non-prescription medicinal products, could affect public health, were it to be excessiveand ill-considered. Advertising of medicinal products to the general public, where it is permitted, ought therefore to satisfy certainessential criteria which ought to be defined.[34]Even before this blanket prohibition came into force within the European Union, many national jurisdictions had adopted into theirproduct liability laws some variant of the American learned intermediary rule, whereby pharmaceutical suppliers were under aduty to warn only the physician intermediary, not the patient. Such rules essentially immunised the pharmaceutical manufacturer inmost failure-to-warn cases. Injured, uninformed patients were expected to proceed against the doctor for negligence, typically forlack of informed consent.[35]

Institutionalised Asymmetric Information


7/8

The effect of these regulations is not to protect the public from charlatans. As said, the Internet is already full of charlatans. Theireffect is to prevent informed discussion of pharmaceutical issues of a kind that ordinary people can understand. Because thepharmaceutical companies are prohibited by law from communicating directly with the public, the public must trust either whatinformation is transmitted via the medical profession, or the wild claims of Internet salesmen based in the British Virgin Islands. Atthe same time, the pharmaceutical companies cannot reach out directly; they cannot truly know what their customers want. Asystem of regulation devised to solve the problem of asymmetric information has set this asymmetricity in legal concrete.Look again at the Internet claims about Prozac as an appetite suppressant. Anyone who thinks it can help with dieting may bemisinformed. Whatever the case, Eli Lilly, the manufacturer of the product, is not allowed to publish a word about the correct uses

of Prozac.Again, there are websites that denounce the products of the pharmaceutical companies and instead recommend products that maybe useless or actually harmful. These products include psychic surgery, faith healing, laetrile, and much else.In 2004, the Journal of Medical Internet Researchpublished a survey of websites providing information on complementary andalternative medicine. The researchers found that:We found that most CAM Web sites were potentially harmful either by displaying statements which could cause harm, or byomitting vital information. However, our data suggest that available technical quality criteria fail to identify potentially harmfulinformation online.We found that one quarter of CAM Web sites present information that may cause physical harm if acted upon. These sitesencouraged consumers to avoid conventional therapy, presented information on products that may be directly toxic, or presentedinformation on products that may cause interactions with conventional medications. This is potentially dangerous becauseconsumers have easy access to CAM products online and act upon what they see on the Internet., often do so without theknowledge or advice of clinicians.

Almost all (97%) CAM Web sites omitted vital warnings, drug interactions, contraindications, or adverse reactions. This isconcerning because many consumers perceive "natural" products as safe. Further, many herbs that may be safe when used aloneinteract with conventional medications.[36]The pharmaceutical companies are often prevented by law from replying in detail to these claims, and from offering their ownopinion about the effectiveness and best use of their own products. Anyone can set up a website to claim that Viagra can cure lungcancer. Pfizer, which developed the product, is not allowed within the European Union to say on its own website how it should bestbe used. Nor is there legal room for any other organisation independent of Pfizer or the regulators to speak authoritatively to thepublic.

Let the Public Speak and Decide

We need a regulatory framework within which the pharmaceutical companies can speak directly with ordinary people, and in whichordinary people can tell the companies and each other about the medicines they want, and about what they hope from themedicines that are available.This means no regulatory framework other than that provided by the common law of tort and contract. The modes of regulationpresently in place have failed. They cannot be reformed. It is better to scrap them and return to the practice of the past. Thereshould be no control on the advertising and sale of any pharmaceutical product. Adults should be able to wander into a pharmacistand buy whatever they please. Doubtless, most people would continue to consult their doctors - but the advice given would bepurely advice, and prescriptions would be purely reminders of that advice.In such a market, the pharmaceutical companies would have to direct their advertising not at small groups of professionals, as atpresent, but at the final users of their products. The purpose of liberalisation here is to enable the growth of a conversationbetween producers and consumers. After all, it is frequently hard to tell the difference between commercial and ordinary speechsee, for example, those front organisation web sites set up Schering Healthcare and Biogen Ltd.It may be said that people really are not able to know what they want, or to understand the nature of what is offered to them.Whether this is a patronising assumption of superiority is beside the point. What does matter is that it is probably a false belief.Ordinary people may not be able to understand all the scientific details of a new pharmaceutical product, but they are surely able todecide whether it is right for them, and whether it is being offered in the way that they want. It is wrong to assume that aninformed decision must rest on full information. Every consumer market in the world is filled with informed consumers who havenothing approaching full information. Hardly anyone in the world knows how a refrigerator works. They still somehow work outwhat capacity, size and shape and colour of refrigerator they want in their kitchens. Even fewer people know how a mobiletelephone works. And yet the average child of ten can explain what he wants from a mobile telephone, and which brand andnetwork come closest to giving that. And these are in markets where no controls exist on what information may be given orexchanged.Informed decisions do not require full information. They require information relevant to the decision. What is relevant depends onwhat is wanted from a product and on the capacity of individual consumers. These are facts that cannot be known to any outside

agency, and cannot be known in advance. We can be sure, however, that, where matters of health or even life itself are concerned,consumers will on the whole make very informed decisions. Anyone who looks at the range of magazines available on consumerelectronic products, on the detailed answers within them to questions put by the readers, and on the serious attention thesemagazines receive from people of apparently limited education, can imagine what would happen were the pharmaceutical marketopened to the same public scrutiny and dialogue as any other market.The normal objection to liberalising the market in pharmaceutical products - that large numbers of people would buy recreationaldrugs and thereby wreck their lives - is not worth discussing. It is not worth discussing because everyone knows that recreationaldrugs are already freely available to anyone inclined to break a few barrely-enforced laws.

http://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah

+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=false
http://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=false


8/8

http://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah

+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=false
http://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=falsehttp://books.google.co.in/books?id=hlQ56RuhSuAC&pg=PA254&dq=pharma+management+biren+shah+export&hl=en&sa=X&ei=5YKeT6DQBorJrAeCvqBh&ved=0CEEQ6AEwAA#v=onepage&q&f=false

Documents

Top 20 Pharmas